Literature DB >> 35862708

The Role of the VP4 Attachment Protein in Rotavirus Host Range Restriction in an In Vivo Suckling Mouse Model.

Liliana Sánchez-Tacuba1,2,3, Takahiro Kawagishi1,2,3, Ningguo Feng1,2,3, Baoming Jiang4, Siyuan Ding5, Harry B Greenberg1,2,3.   

Abstract

The basis for rotavirus (RV) host range restriction (HRR) is not fully understood but is likely multigenic. RV genes encoding VP3, VP4, NSP1, NSP2, NSP3, and NSP4 have been associated with HRR in various studies. With the exception of NSP1, little is known about the relative contribution of the other RV genes to HRR. VP4 has been linked to HRR because it functions as the RV cell attachment protein, but its actual role in HRR has not been fully assessed. We generated a collection of recombinant RVs (rRVs) in an isogenic murine-like RV genetic background, harboring either heterologous or homologous VP4 genes from simian, bovine, porcine, human, and murine RV strains, and characterized these rRVs in vitro and in vivo. We found that a murine-like rRV encoding a simian VP4 was shed, spread to uninoculated littermates, and induced diarrhea comparably to rRV harboring a murine VP4. However, rRVs carrying VP4s from both bovine and porcine RVs had reduced diarrhea, but no change in fecal shedding was observed. Both diarrhea and shedding were reduced when VP4 originated from a human RV strain. rRVs harboring VP4s from human or bovine RVs did not transmit to uninoculated littermates. We also generated two rRVs harboring reciprocal chimeric murine or bovine VP4. Both chimeras replicated and caused disease as efficiently as the parental strain with a fully murine VP4. These data suggest that the genetic origin of VP4 partially modulates HRR in the suckling mouse and that both the VP8* and VP5* domains independently contribute to pathogenesis and transmission. IMPORTANCE Human group A rotaviruses (RVs) remain the most important cause of severe acute gastroenteritis among infants and young children worldwide despite the introduction of several safe and effective live attenuated vaccines. The lack of knowledge regarding fundamental aspects of RV biology, such as the genetic basis of host range restriction (HRR), has made it difficult to predictively and efficiently design improved, next-generation live attenuated rotavirus vaccines. Here, we engineered a collection of VP4 monoreassortant RVs to systematically explore the role of VP4 in replication, pathogenicity, and spread, as measures of HRR, in a suckling mouse model. The genetic and mechanistic bases of HRR have substantial clinical relevance given that this restriction forms the basis of attenuation for several replication-competent human RV vaccines. In addition, a better understanding of RV pathogenesis and the determinants of RV spread is likely to enhance our ability to improve antiviral drug and therapy development.

Entities:  

Keywords:  host range restriction; pathogenesis; reverse genetics; rotavirus; transmission; viral replication

Mesh:

Substances:

Year:  2022        PMID: 35862708      PMCID: PMC9364800          DOI: 10.1128/jvi.00550-22

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  44 in total

1.  Rotavirus Controls Activation of the 2'-5'-Oligoadenylate Synthetase/RNase L Pathway Using at Least Two Distinct Mechanisms.

Authors:  Liliana Sánchez-Tacuba; Margarito Rojas; Carlos F Arias; Susana López
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

2.  Rotavirus NSP1 mediates degradation of interferon regulatory factors through targeting of the dimerization domain.

Authors:  Michelle M Arnold; Mario Barro; John T Patton
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

Review 3.  The Rotavirus Interferon Antagonist NSP1: Many Targets, Many Questions.

Authors:  Michelle M Arnold
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

4.  Global Impact of Rotavirus Vaccination on Diarrhea Hospitalizations and Deaths Among Children <5 Years Old: 2006-2019.

Authors:  Eleanor Burnett; Umesh D Parashar; Jacqueline E Tate
Journal:  J Infect Dis       Date:  2020-10-13       Impact factor: 5.226

5.  Reverse Genetics Approach for Developing Rotavirus Vaccine Candidates Carrying VP4 and VP7 Genes Cloned from Clinical Isolates of Human Rotavirus.

Authors:  Yuta Kanai; Misa Onishi; Takahiro Kawagishi; Pimfhun Pannacha; Jeffery A Nurdin; Ryotaro Nouda; Moeko Yamasaki; Tina Lusiany; Pattara Khamrin; Shoko Okitsu; Satoshi Hayakawa; Hirotaka Ebina; Hiroshi Ushijima; Takeshi Kobayashi
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

6.  Determinants of rotavirus host range restriction--a heterologous bovine NSP1 gene does not affect replication kinetics in the pig.

Authors:  J C Bridger; W Dhaliwal; M J Adamson; C R Howard
Journal:  Virology       Date:  1998-05-25       Impact factor: 3.616

7.  Murine rotavirus genes encoding outer capsid proteins VP4 and VP7 are not major determinants of host range restriction and virulence.

Authors:  R L Broome; P T Vo; R L Ward; H F Clark; H B Greenberg
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

8.  Permissive replication of homologous murine rotavirus in the mouse intestine is primarily regulated by VP4 and NSP1.

Authors:  Ningguo Feng; Linda L Yasukawa; Adrish Sen; Harry B Greenberg
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

9.  Generation of simian rotavirus reassortants with diverse VP4 genes using reverse genetics.

Authors:  Alexander Falkenhagen; Corinna Patzina-Mehling; Antje Rückner; Thomas W Vahlenkamp; Reimar Johne
Journal:  J Gen Virol       Date:  2019-12       Impact factor: 3.891

10.  C3P3-G1: first generation of a eukaryotic artificial cytoplasmic expression system.

Authors:  Philippe H Jaïs; Etienne Decroly; Eric Jacquet; Marine Le Boulch; Aurélien Jaïs; Olivier Jean-Jean; Heather Eaton; Prishila Ponien; Fréderique Verdier; Bruno Canard; Sergio Goncalves; Stéphane Chiron; Maude Le Gall; Patrick Mayeux; Maya Shmulevitz
Journal:  Nucleic Acids Res       Date:  2019-03-18       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.